TABLE 1.

Patient characteristics of the cohort at baseline

	Total	RD	IBD	Psoriasis
No patients (%)	2228	1155	967	106
Females (%)	1261 (56.6%)	705 (61.0%)	515 (53.3%)	41 (38.7)
Median age (IQR) (years)	43.3 (26.8–57.2)	49.1 (33.3–70.0)	34.4 (22.5–51.2)	50.6 (34.4–60.4)
Etanercept	573 (25.7%)	549 (47.5%)	—	24 (22.7%)
Infliximab	654 (29.3%)	41 (3.6%)	603 (62.4%)	10 (9.4%)
Adalimumab	911 (40.9%)	488 (42.3%)	351 (36.3%)	72 (67.9%)
Certolizumab	13 (0.6%)	13 (1.1%)	—	—
Golimumab	77 (3.5%)	64 (5.5%)	13 (1.3%)	—
Baseline use of immunomodulator	1105 (49.6%)	671 (58.1%)	417 (43.1%)	17 (16.0%)
Median follow‐up (IQR) (years)	3.4 (2.1–5.0)	3.6 (2.2–5.2)	3.3 (2.0–4.8)	3.2 (2.1–4.5)

Abbreviation: IQR, interquartile range.